Inhibition of hypoxia-inducible factor-1α alleviates acinar cell necrosis in a mouse model of acute pancreatitis

被引:8
|
作者
Shen, Qinhao [1 ]
Shi, Xiaolei [1 ]
Tao, Lide [2 ]
Zhu, Qingtian [1 ]
Xiao, Weiming [1 ]
Ding, Yanbing [1 ]
Gong, Weijuan [1 ]
Lu, Guotao [1 ]
Wang, Mei [1 ]
Yao, Guanghuai [1 ]
机构
[1] Yangzhou Univ, Affiliated Hosp, Dept Gastroenterol, Pancreat Ctr, Yangzhou, Jiangsu, Peoples R China
[2] Yangzhou Univ, Affiliated Hosp, Dept Surg, Yangzhou, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Acute pancreatitis; Acinar cell; Hif1; alpha; Necroptosis; MIXED LINEAGE KINASE; DOMAIN-LIKE; NECROPTOSIS; DOWNSTREAM; TARGET; MLKL;
D O I
10.1016/j.bbrc.2021.07.043
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxia-inducible factor-1 alpha (Hif1 alpha) is activated in hypoxia and is closely related to oxidative stress, immunity and cell metabolism. Recently, it is reported that Hif1 alpha is involved in atherosclerosis, ischemiareperfusion (I/R) injury, alcoholic liver disease and pancreatic tumors. In this study, we found that Hif1 signal pathway is significantly changed in pancreas of acute pancreatitis (AP) mice. Meanwhile, we verified that the high expression of Hif1 alpha injured pancreatic tissues of cerulean-induced AP mice, which prompting that Hif1 alpha participated in the progress of histopathology on AP. We applied a Hif1 alpha inhibitor PX478 and observed that it could alleviate histological injury of pancreas as well as the levels of serum amylase, lipase and proinflammatory cytokine in the murine model of AP induced by caerulein. In addition, PX478 could reduce the formation of necrosome (RIP3 and p-MLKL) and the generation of reactive oxygen species (ROS) in AP mice. Correspondingly, we further confirmed the effectiveness of PX478 in vitro and found that inhibiting Hif1 alpha could mitigated the necrosis of pancreatic acinar cells via reducing the RIP3 and p-MLKL expression and the ROS production. In conclusion, inhibiting Hif1 alpha could protect against acinar cells necrosis in AP, which may provide a new target for the prevention and treatment of AP clinically. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:72 / 79
页数:8
相关论文
共 50 条
  • [41] Hypoxia-inducible factor-1 as a therapeutic target in cancer
    Tang, Ceen-Ming
    Yu, Jun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (03) : 401 - 405
  • [42] Hypoxia-inducible factor-1 regulation and therapeutic implication
    Rustum, Youcef M.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S9 - S9
  • [43] Tetrathiomolybdate mediates the degradation of hypoxia-inducible factor-1α
    Kim, Kyu Kwang
    Abelman, Sarah
    Yano, Naohiro
    Ribeiro, Jennifer R.
    Singh, Rakesh K.
    Tipping, Marla
    Moore, Richard G.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 590 - 590
  • [44] Living kidney donors and hypoxia-inducible factor-1α
    Baan, C
    van Gelder, T
    Peeters, A
    Mol, W
    Niesters, H
    Weimar, W
    IJzermans, J
    TRANSPLANTATION, 2003, 75 (04) : 570 - 571
  • [45] Hypoxia-inducible factor-1 regulation of myeloid cells
    Stothers, C. L.
    Luan, L.
    Fensterheim, B. A.
    Bohannon, J. K.
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2018, 96 (12): : 1293 - 1306
  • [46] The Role of Hypoxia-inducible Factor-1 in Bladder Cancer
    Chai, Jiagui
    Yin, Sifan
    Feng, Wenbo
    Zhang, Tao
    Ke, Changxing
    CURRENT MOLECULAR MEDICINE, 2024, 24 (07) : 827 - 834
  • [47] Targeting hypoxia-inducible factor-1 for therapy and prevention
    Zhong, H
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (07) : 951 - 966
  • [48] A role for hypoxia-inducible factor-1α in desferoxamine neuroprotection
    Hamrick, SEG
    McQuillen, PS
    Jiang, XN
    Mu, DZ
    Madan, A
    Ferriero, DM
    NEUROSCIENCE LETTERS, 2005, 379 (02) : 96 - 100
  • [49] Hypoxia-Inducible Factor-1α and Autoimmune Lupus, Arthritis
    Zu-Cheng Yang
    Yi Liu
    Inflammation, 2016, 39 : 1268 - 1273
  • [50] The Role of Hypoxia-Inducible Factor-1α in Acetaminophen Hepatotoxicity
    Sparkenbaugh, Erica M.
    Saini, Yogesh
    Greenwood, Krista K.
    LaPres, John J.
    Luyendyk, James P.
    Copple, Bryan L.
    Maddox, Jane F.
    Ganey, Patricia E.
    Roth, Robert A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (02): : 492 - 502